Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Ric Stanulis"'
Autor:
Kimberly M. Freeman, Jennifer Iaci, Jonathan P. Jackson, Andrew Eisen, Ric Stanulis, Donald Button, Paul B. Watkins, Anthony O. Caggiano, Merrie Mosedale, Tom J. Parry, Kenneth R. Brouwer, Maya Srinivas
Publikováno v:
Toxicological Sciences. 161:401-411
GGF2 is a recombinant human neuregulin-1β in development for chronic heart failure. Phase 1 clinical trials of GGF2 were put on hold when transient elevations in serum aminotransferases and total bilirubin were observed in 2 of 43 subjects who recei
Autor:
Grant T. Generaux, Donald Button, Ric Stanulis, Anthony O. Caggiano, Brett A. Howell, Diane M. Longo, Merrie Mosedale, Daniel J. Antoine, Tom J. Parry, Paul B. Watkins, Andrew Eisen, Scott Q. Siler, Jennifer Iaci
Publikováno v:
Longo, D M, Generaux, G T, Bengry-Howell, A, Siler, S Q, Antoine, D, Button, D, Caggiano, J A, Eisen, J A, Iaci, J, Stanulis, R, Parry, T, Mosedale, M & Watkins, P B 2017, ' Refining Liver Safety Risk Assessment : Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials ', Clinical pharmacology and therapeutics, vol. 102, no. 6, pp. 961-969 . https://doi.org/10.1002/cpt.711
Clinical Pharmacology and Therapeutics
Clinical Pharmacology and Therapeutics
Cimaglermin alfa (GGF2) is a recombinant human protein growth factor in development for heart failure. Phase I trials were suspended when two cimaglermin alfa-treated subjects experienced concomitant elevations in serum aminotransferases and total bi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdd70ea640db5a0d3acd2dc98e1dfc91
https://www.pure.ed.ac.uk/ws/files/55790946/Antoine_D_Refining_Liver_Safety....pdf
https://www.pure.ed.ac.uk/ws/files/55790946/Antoine_D_Refining_Liver_Safety....pdf